Search results
Showing 391 to 405 of 661 results for diabetes
This quality standard covers managing hypertension in adults. It includes diagnosis and investigations, treatment and specialist referral. It describes high-quality care in priority areas for improvement.
View quality statements for QS28Show all sections
Sections for QS28
- Quality statements
- Quality statement 1: Diagnosis – ambulatory blood pressure monitoring
- Quality statement 2: Investigations for target organ damage
- Quality statement 3: Statin therapy
- Quality statement 4: Blood pressure targets
- Quality statement 5: Review of cardiovascular disease risk factors
- Quality statement 6: Referral to a specialist for adults with resistant hypertension
- Update information
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
None. Source guidance details Comes from guidance Type 2 diabetes prevention: population and community-level interventions Number
Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)
NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input
This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
would monitor and evaluate the rates of Charcot arthropathy resulting from diabetes, rates and extent of amputation (major or minor),...
would monitor and evaluate the cure rates of foot ulcer resulting from diabetes, rates and extent of amputation (major or minor),...
monitor and evaluate the rates of foot ulcer or infection resulting from diabetes, rates and extent of amputation (major or minor),...
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
View recommendations for MPG2Show all sections
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.
This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .